The February medical journal Prescrire draws up a new list of drugs that are more dangerous than useful. The famous medical journal calls for the withdrawal of these drugs from the market.
Review Prescribe unveiled Thursday its list of “medications
more dangerous than useful “. The famous medical journal calls for the withdrawal of the
market for these medicines which put consumers at risk
health disproportionate to the benefits they bring.
are new, others are more or less old but still authorized,
available and promoted “, explains the independent review. This list
includes several dozen drugs, which the review considers necessary to withdraw
of the market.
This list was drawn up on the basis of analyzes published in the review of
2010 to 2012. In its February issue, Prescribe devotes a special file that it
available to readers free of charge.
the dihydroergocryptin (in Vasobral®), *dihydroergocristine
- (Iskedyl®), the dihydroergotoxin (Hydergine®), the nicergoline
(Sermion® or other).
Cancerology – Hematology:
the catumaxomab (Removab®); the panitumumab (Vectibix®);
the trabectedin (Yondelis®), the vandetanib (Caprelsa®),
the vinflumine (Javlor®), the iron dextran (Ferrisat®).
Dermatology – Allergology:
the tacrolimus dermal (Protopic®); the mequitazine (Primalan®);
the promethazine injectable (Phenergan®).
Diabetology – Nutrition:
the saxagliptin (Onglyza®), the sitagliptin (Januvia®,
Xelevia®) and the vildagliptin (Galvus®); I’orlistat (Xenical®
Gynecology – Endocrinology:
the tibolone (Livial®)
the domperidone (Motilium® or other).
the moxifloxacin (Izilox®), the telithromycin (Ketek®).
the flunarizine (Sibelium®) and theindoramine
(Vidora®); the natalizumab (Tysabri®), the *tolcapone